Areas under ROC curves analysis of DTI and MRSI derived measures in different groups of MS patients.

<p>Statistical significance (*p<0.05; **p<0.01; ***p<0.001) when comparing areas under ROC curves (AUC) of the following MR metrics: MD: mean diffusivity, λr: radial diffusivity, NAA: N-acetylaspartate, Cr: creatine, RR: relapsing remitting; SP: secondary progressive; PP: primary progressive.</p

Demographics and group characteristics.

<p>Values are expressed as mean (Standard deviation).</p><p>RR: relapsing remitting; SP: secondary progressive; PP: primary progressive; EDSS: expanded disability status scale; ROI T2-LL: T2-lesion load corresponding to the lesion volume measured within the region of interest (ROI); Brain T2-LL: T2-lesion load corresponding to the lesion volume measured in the whole brain.</p

ROC curves of the mean diffusion (MD), axial (λa) and radial (λr) diffusivities, NAA/Cho and NAA/Cr ratios in RR (A), SP (B), PP (C) and all-MS patient groups (D).

<p>ROC curves of the mean diffusion (MD), axial (λa) and radial (λr) diffusivities, NAA/Cho and NAA/Cr ratios in RR (A), SP (B), PP (C) and all-MS patient groups (D).</p

Correlation rates (r) between diffusion and metabolic measures and the ROI T2-LL in different groups of MS patients.

<p>Correlation significance (*p<0.05; **p<0.01; ***p<0.001).</p><p>ROI T2-LL: T2-lesion load corresponding to the lesion volume within the region of interest, MD: mean diffusion, FA: fraction of anisotropy, λa: axial diffusivity, λr: radial diffusivity, NAA: N-acetylaspartate, Cr: creatine, RR: relapsing remitting; SP: secondary progressive; PP: primary progressive.</p

Diffusion and metabolic measures in MS patients and control subjects groups.

<p>Values (Mean ± SD) of mean diffusion (MD), fraction of anisotropy (FA), axial (λa) and radial (λr) diffusivities, N-acetylaspartate (NAA), choline (Cho) and creatine (Cr) (*p<0.05; **p<0.01; ***p<0.001 when compared to controls). RR: relapsing remitting; SP: secondary progressive; PP: primary progressive.</p

Correlations between radial diffusivity (λr) and NAA/Cr ratio with the ROI T2-LL in RR, PP and all-MS patient groups. (NS = Not significant).

<p>Correlations between radial diffusivity (λr) and NAA/Cr ratio with the ROI T2-LL in RR, PP and all-MS patient groups. (NS = Not significant).</p

Changes of BOLD signal related to Mirror Movements.

<p>Abbreviations : L : left, R : right, BA : Brodmann’s Area</p

BOLD signal changes related to Mirror Movements.

<p><b>A:</b> Reduction of activation during MM (PD+MM B: Increase of activation during MM (PD+MM >PD-MM). Graphs show the regionally averaged beta weights across patients from each group. Error bars indicate inter-patient standard error of the mean (SEM). L = left; R = right.</p

Changes of BOLD signal related to Parkinson’s disease.

<p>Abbreviations : L = left; R = right; BA = Brodmann’s area</p

Clinical characteristics of PD patients and controls.

<p>Levodopa Eq = levodopa equivalent: 100 mg L-dopa = 10 mg Bromocriptine = 5mg Ropinirole = 1 mg Pergolide = 50 mg Piribedil = 1 mg Pramipexole <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0066910#pone.0066910-Thobois2" target="_blank">[20]</a>; SD: Standard Deviation;</p>*<p>p<0.05.</p